Gimeracil is a DPD inhibitor used as an adjunct to antineoplastic therapy to increase the systemic concentrations and therapeutic effectiveness of other antineoplastic agents. Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the main active componets within chemotherapy regimens.
- Mechanism
- Curator reviewed · 2 references
Gimeracil's main role within Teysuno is to prevent the breakdown of DB00544 (5-FU), which helps to maintin high enough concentrations for sustained effect against cancer cells. It functions by reversibly blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU.
- Primary indication
- Gimeracil is used as an adjunct to antineoplastic therapy.Curator reviewed · 1 structured indication
- Formula / weight
- C5H4ClNO2 · 145.54 g/mol (avg)
- First approval
- European Union, 2016
- Also known as
- gimestat · Teysuno
- Code names
- Ts-1 (TN)
- Brand names
Resolves to
ZPLQIPFOCGIIHV-UHFFFAOYSA-NSMILESOC1=CC(=O)NC=C1ClWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Gimeracil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account